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ABSTRAK
Leukemia myeloid kronis (CML) adalah kelainan sel punca hemopoietik klonal dengan translokasi resiprokal 
dalam kromosom 9 (ch9) dan 22 (ch22) yang menyebabkan fusi cluster Break-Abelson murine leukemia (BCR-
ABL) onkogen. Penggabungan ini akan mengaktifkan tirosin kinase. Imatinib mesylate adalah inhibitor tirosin 
kinase (TKI) pertama yang dapat mengubah prognosis pasien CML. Namun, ada penolakan terhadap TKI, dan 
berdasarkan studi transkriptomik, peningkatan ekspresi transduser sinyal gen dan aktivator transkripsi (STAT) 
5A dan faktor transkripsi terkait runt (RUNX3) dapat menyebabkan resistansi terhadap TKI. Protein STAT5, 
yang dalam sel-sel myeloid normal diaktifkan oleh sitokin, pada pasien CML diaktifkan bahkan tanpa sitokin. 
STAT5 merujuk pada STAT5A dan STAT5B, namun mereka mungkin memiliki peran yang berbeda dalam sel 
induk hematopoietik atau dalam sel CML. Ulasan ini merangkum peran STAT5 dalam resistensi inhibitor tirosin 
kinase pada pasien CML.
Kata kunci: leukemia myeloid kronis, STAT5, Imatinib, inhibitor tirosin kinase, resisten.
ABSTRACT
Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation 
in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia 
(BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the first tyrosine kinase 
inhibitor (TKI), which could change the prognosis of CML patients. However, there is a resistance to TKI’s, 
and based on transcriptomic study, increase expression of gen signal transducer and activator of transcription 
(STAT) 5A and runt-related transcription factor 3 (RUNX3) can cause resistance to TKI’s. The STAT5 protein, 
which in normal myeloid cells being activated by cytokine, in CML patients was activated even without cytokines. 
STAT5 refer to STAT5A and STAT5B, however they have might have different role in hematopoietic stem cells or 
in CML cells. This review summarizes the role of STAT5 in tyrosine kinase inhibitor resistance in CML patients. 
Keywords: chronic myeloid leukemia, STAT5, Imatinib, tyrosine kinase inhibitor, resistance.
INTRODUCTION
Chronic myeloid leukemia (CML) is one 
of myeloproliferative neoplasm. Fusion of 
the Abelson murine leukemia (ABL1) gene 
on chromosome 9 with the breakpoint cluster 
region (BCR) gene on chromosome 22 in CML 
express as BCR-ABL1 oncogene.1 The BCR-
ABL1 through downstream signaling pathways 
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such as RAS, RAF, JUN kinase, MYC, and 
STAT activate the tyrosine kinase continually, 
which creating cytokine independent cell cycle.2 
This Highly active tyrosine kinase are aim for 
survival of the cells, increase cells proliferation, 
increase resistance against apoptosis and 
changes in adhesion feature.3 Since then there 
was so many study were done to blockade the 
activity of tyrosine kinase. Until in 1996 the 
first tyrosine kinase imatinib been found, which 
is imatinib mesylate (IM) (Gleevec, Novartis 
Pharmaceutical Corporation, NJ, USA).4
Since the discover of imatinib mesylate (IM) 
the survival of CML patients are improving, 
which make IM one of the first line therapy for 
CML.4 However objective measurement was 
needed to evaluate the response of IM treatment, 
such as hematologic response, cytogenetic 
response and molecular response. Response of 
the treatment need to be evaluated every 3, 6, 12 
months.5 However there is some population of 
CML patients have IM resistance. Poor response 
of IM led to the discover of newer generation of 
tyrosine kinase inhibitors (TKIs) of BCR-ABL, 
such as dasatinib, nilotinib, and bosutinib or 
even new class of treatment based on the cause 
of the resistance.6 The resistance to imatinib can 
be differ to primary and secondary.4
There are several risk factor for imatinib 
secondary resistance such as point mutation in 
BCR-ABL or over expression of BCR-ABL. 
However, from transcriptomic study there are 
increase in STAT5A and RUNX3 expression.7 
STAT5 protein is transcriptional factor in 
cytoplasm or cell nuclear , which can be activated 
even without cytokine in CML.4 There are four 
major roles of STAT5, first to stimulate cells 
proliferation, to increase viability of the cell, to 
neutralized cell death due to TKI and increase 
the possibility of mutation in BCR-ABL1.4 
This led to hypothesis that STAT5 have a role 
in IM resistance. Recently a study discovers 
an inhibitor for STAT5, known as Pimozide. 
Resistance of IM led us to do various study with 
different approach, such as knowing the role of 
STAT5 in CML with IM resistance.
TREATMENT RESPONSE IN CHRONIC 
MYELOID LEUKEMIA
There are three treatment response that 
could be monitor while administered TKI, first 
hematologic response to observe the normalization 
of peripheral blood counts, second cytogenic 
response to observe the decrease in the number 
of Ph-positive metaphases using bone marrow 
cytogenetic, and third molecular responds. The 
responses in molecular response divided into 
three, first early molecular response (EMR) 
which is BCR-ABL1(IS) <10% at 3-6 months, 
second major molecular response (MMR) which 
is BCR-ABL1(IS) <0.1 % or >3-log reduction in 
BCR-ABL1 mRNA from the standarize baseline, 
and third complete molecular response (CMR) 
which variably described.5 The prognostic value of 
MMR is slightly higher than complete cytogenic 
response (CCyR) in foreseeing progression free 
survival and overall survival, however if we did 
longer time of follow up CCyR become more 
stronger indicator than MMR. Achievement of 
CCyR within 12 months and no progression of 
the diseases into acute phase CML or blast phase 
CML are the goal of TKI therapy.5 The response 
milestone based on National Comprehensive 
Cancer Network are shown in Table 1.5
PATOPHYSIOLOGY OF RESISTANCE
As we know resistance of IM are divided 
into primary and secondary resistance. Primary 
resistance is when the patient failure to achieve 
the response from the guideline such as NCCN. 
Primary resistance divided into primary 
Table 1. Milestone Response5
BCR-ABL1 (IS) 3 months 6 months 12 months > 15 months
>10% Possible TKI resistance TKI resistant
>1-10% TKI Sensitive disease Possible TKI resistance TKI resistant
<1% TKI Sensitive disease
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hematologic resistance or primary cytogenic 
response. Secondary resistance or also known 
as acquired resistance happens when previously 
achieved the target response than subsequently 
lost the response. However, the mechanism of 
resistance divided by BCR-ABL dependent such 
as gene amplification or point mutations or BCR-
ABL independent.8
The cause of primary resistance is plasma 
low level of IM, low level of intracell uptake 
of IM and clonal evolution. Hence the cause of 
secondary resistance is point mutation or over 
expression of BCR-ABL.4
BCR-ABL Dependent. Point mutation in 
the BCR-ABL is the most common cause of 
secondary resistance which also responsible for 
treatment failure. Around 100 points mutation 
already found such as T315I, Y253H and 
F255K. T315I is the most common compare 
to other point mutation and seen in 4-15% 
patients off patients who resistance to imatinib. 
The active form of BCR-ABL oncoprotein can 
caused by point mutations it also can causing 
change in the imatinib binding site, to prevent 
binding of imatinib and can also remove critical 
molecules required for bonding, thus reduce its 
efficacy.8 Other BCR-ABL depended cause is 
amplification of the ABL-kinase. Reactivation 
of BCR-ABL signal transduction is another 
mechanism of resistance and has been associated 
with both BCR-ABL point mutations and gene 
amplification.8
BCR-ABL-independent .  BCR-ABL 
independent mechanism involve increase 
expression of P-glycoprotein efflux pumps can 
cause increased efflux of the drug. Efflux of 
the drug also can increase by overexpression 
of the P-170 glycoprotein, and can reduces 
intracellular drug accumulation, decreased 
drug uptake secondary to decreased expression 
of the drug uptake transporter human organic 
cation transporter 1 (hOCT1), and activation 
of the alternative signaling pathway such as 
Ras/Raf/MEK kinase, STAT, Erk2, or SFK 
phosphorylation of BCR-ABL.4,8 STAT5 protein 
also thought as one of the mechanism of BCR-
ABL independent for secondary IM resistant.
TRANSDUCER SIGNAL AND ACTIVATOR 
OF TRANSCRIPTION 5 (STAT5)
STAT protein is a transcriptional factor, 
which are in the cytoplasmic and nuclear cell 
compartments. STAT is structurally conserved 
and essential for carrying out multiple cellular 
functions in response to extracellular cytokines 
and growth factors signals. STAT have 6 
domains, from STAT1, STAT2, STAT3, STAT4, 
STAT5 (STAT5A and STAT5B) and STAT6.9 
STATs have two major function which is 
activating transcription of diverse set of genes 
include genes that involved in malignancy 
and transducing cellular signals. Because of 
enforced upstream kinase signals, STATs are 
active in hematologic malignancy especially 
myeloproliferative neoplasm, leukemia and solid 
tumors.10 In year 1996 Van Etten reported that 
STAT5 directly activated by CML cell induced 
by BCR-ABL, which usually activated by JAK 
pathways.11
STAT5 known to have several major roles 
in hematopoietic and immune cell functions 
such as cells proliferation, differentiation, and 
apoptosis.10 STAT5 can be activate in normal 
condition usually by cytokine such as growth 
factor through JAK-STAT pathways but also can 
dysregulated in leukemic hematopoiesis or other 
hematologic malignancy.10 STAT5 is activated 
by phosphorylation of a single tyrosine residue 
such as Y694 in STAT5A and Y699 in STAT5B.12 
However, STAT5 negatively regulated by 
dephosphorylation.10
Triggered by the BCR-ABL1 oncoprotein, 
STAT5 have four roles to support CML. First is 
the capability of stimulating cell proliferation. 
Second to enhances cell viability by upregulation 
of anti-apoptotic genes such as BCLXL and 
MCL1. Third the ability to counteract TKI-
induced cell death and last to increase the 
probability of acquiring BCRABL1 mutations.13 
The last two just being discovered recently. 
In CML, the expression of the Bcr-abl fusion 
protein trigger consecutive activation of tyrosine 
kinase which lead to persistent activation 
of STAT5.10 STAT5 also can be persistently 
activated by JAK2 and JAK3 mutations, Src 
Vol 51 • Number 4 • October 2019                    The role of STAT5 in tyrosine kinase inhibitor resistance in CML patients
351
family kinases (SFKs) and in particular, c-Src 
through growth factor receptor signaling, which 
is different from the cytokine receptor signaling 
in the JAK pathway.14-6
Persistent activation of STAT5 related 
with ROS through various mechanism, the 
mechanism independent of JAK2.17-18 STAT5 
signaling also promotes ROS formation by 
repressing expression of antioxidant enzymes 
including catalase and glutaredoxin-1 (Glrx1) 
in Bcr-Abl-positive CML.10 However Cassetti 
et al, reported that STAT5 especially STAT5A is 
protective against oxidative stress, observed by 
the knockdown of STAT5A increased the basal 
level ROS production and subsequently genomic 
stress in CML cell lines, while STAT5B have 
different contribution to stress protection.19
There are two isoforms of STAT5, STAT5A 
and STAT5B, which have high sequence 
homology and have 96% similarity in the protein 
level.20 STAT5A and STAT5B are encoded by 
two different gene, however both located in the 
chromosome 17 in human. In human STAT5A 
formed by 20 exons and STAT5B formed by 
19 exons.4 The highest prevalence of STAT5A 
are in mammary tissue, while STAT5B are in 
muscles and liver. In other tissue have same lavel 
of STAT5A and STAT5B. It also been identified 
that location of STAT5A and STAT5B is different 
in CML cells, STAT5A maasively located in 
cytoplasma and STAT5B in nucleus.21
There is several difference of function 
between STAT5A and STAT5B, such as different 
respons to stress and in v-ABL expressing cells 
STAT5B can induce STAT5A expression, hence 
STAT5A cannot induced STAT5B expression.10,19 
Study by Schönitz et al show that there is some 
cytoplasmic retention of STAT5A and not 
STAT5B in the presence of BCR-ABL.20 Also 
from the same study show that interaction of 
STAT5B-BCR-ABL required for the proliferation 
of human cells. When there is a reduce in BCR-
ABL kinase activity, up regulation of STAT5B 
expression may activate STAT5 signaling.20 
There is study shown that STAT5B may use as 
agent for therapeutic in leukemia with BCR-
ABL-positive. Even though inhibitor specific 
for STAT5B are difficult to develop because 
the similarity with STAT5A.22 Study done by 
Zhang et al, when they did transcriptomic study 
and found that only STAT5A and not STAT5B 
as a predictor of secondary imatinib resistance.23
STAT5 as a new target therapy. Resistance of 
imatinib, make it necessary to find new treatment. 
There is an analysis done to identify inhibitors 
of STAT5 seek the transcriptional activity. From 
this approach, the neuroleptic drug pimozide was 
found to inhibit STAT5-dependent reporter gene 
expression. Pimozide is neuroleptic drug used 
to treat Tourette through blockage dopamine 
receptor. Pimozide treatment leads to the loss of 
expression of endogenous STAT5 target genes 
that can promote malignant cellular behavior, but 
do not affect BCR/ABL phosphorylation, unlike 
imatinib who can reduce the phosphorylation of 
STAT5 and phosphorylation of BCR/ABL.
CONCLUSION
In CML patient treatment with imatinib, 
which a first-generation TKI is the first line 
treatment, and give a good outcome. However, 
the response is not the same in some patients, 
and they were diagnosed as imatinib resistance. 
Resistance of imatinib divided by primary 
and secondary or BCR-ABL dependent or 
independent. STAT5 is one thought as one cause 
and predictor of imatinib resistance. STAT5 also 
have four major roles in CML cells, which is to 
stimulate cells proliferation, to increase viability 
of the cell, to neutralized cell death due to TKI 
and increase the possibility of mutation in BCR-
ABL1. Recently a study discovers an inhibitor 
for STAT5, known as Pimozide which could 
led to discover of new target therapy for CML. 
However more study are needed to study the role 
of stat5 in tyrosine kinase inhibitor (imatinib) 
resistance in CML patients.
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